Navigation Links
RXi Pharmaceuticals Announces CEO Interview
Date:7/18/2013

WESTBOROUGH, Mass., July 18, 2013 /PRNewswire/ -- RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, completed an interview with Keith Markey, Ph.D, Equities Analyst with Griffin Securities. During this interview, Dr. Cauwenbergh discusses next steps in the evolution of the company in relation to its anti-scarring compound, RXI-109, and other self-delivering RNAi (sd-rxRNA®) opportunities.

A replay of the interview is available on the "Investors" section of the company's website, www.rxipharma.com/investors/events.        

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTCQX: RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.


'/>"/>
SOURCE RXi Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cree, Intuitive Surgical, Alexion Pharmaceuticals, Roche and Onyx Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
2. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
3. Valeant Pharmaceuticals To Announce 2013 Second Quarter Results On August 7, 2013
4. GW Pharmaceuticals to Report Q3 2013 Results and Host Conference Call on 5 August, 2013
5. RXi Pharmaceuticals Announces Positive Data in Second Phase 1 Multi-Dose Study
6. UCBs Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride
7. Tris Pharmas Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution
8. Breckenridge Announces Dismissal of Various Lawsuits Against Macoven Pharmaceuticals in Return for Macovens Discontinuance of Certain Products
9. Kinex Pharmaceuticals Will Take the Lead in the Orascovery Program Development in China
10. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
11. Vanda Pharmaceuticals to Participate in Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... 2017  A new tight-tolerance microextrusion medical tubing ... materials, is being launched by Natvar, a Tekni-Plex ... in recent years to service a wide variety ... More expensive materials such as glass and fluoropolymers ... to their ability to consistently hold tolerances. This ...
(Date:5/3/2017)... Calif. , May 3, 2017 ... of any hospital or healthcare facility. Commonly referred ... room is equipped with diagnostic imaging technology to ... of the heart. In these spaces, a team ... catheterization, balloon angioplasty, percutaneous coronary intervention, congenital heart ...
(Date:5/3/2017)... , May 3, 2017  Getinge, a ... contribute to quality enhancement and cost efficiency within ... a study of contemporary practice demonstrating that intra-aortic ... therapy for critically ill patients. The single-center, retrospective, ... newer large volume MEGA ® 50cc intra-aortic ...
Breaking Medicine Technology:
(Date:5/21/2017)... PA (PRWEB) , ... May 21, 2017 , ... Following ... 2012, New York became the first state to require that hospitals follow a protocol ... controversy in the medical community as to whether such steps would have saved Rory ...
(Date:5/19/2017)... ... 19, 2017 , ... DMG Productions is proud to announce ... Ed Begley, Jr., airing fourth quarter 2017 on FOX Business. , Based in ... supplement made from naturally occurring ingredients. Innovations will enlighten viewers on RawTrition’s all-in-one ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Miller Agency, ... to families and business owners in the region, is embarking on a cooperative ... and their families. , Multiple sclerosis (MS) is a demyelinating disease that affects ...
(Date:5/19/2017)... ... May 18, 2017 , ... ML Billing, 2016 ... specialties and sizes and specializes in large group practices, is pleased to announce their ... it has also set the standard in all aspects of full-service medical billing. This ...
(Date:5/18/2017)... ... 18, 2017 , ... Dr. Kim Ross supports Stroke Awareness Month by now ... link between this condition and serious systemic health conditions including heart disease and stroke. ... in Annapolis, MD, and seeking treatment with Dr. Ross immediately may prevent bacteria from ...
Breaking Medicine News(10 mins):